Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer. Issue 1 (December 2017)

• Record Type: Journal Article
• Authors: Moschetta, Michele; Mak, Gabriel; Hauser, Joana; Davies, Catriona; Uccello, Mario; Arkenau, Hendrik-Tobias
• Is Part Of: Experimental hematology & oncology. Volume 6:Issue 1(2016)
• Page Start: 1
• Page End: 5
• Publication Date: 2017-12
• Subjects: Dabrafenib -- Trametinib -- BRAF V600E mutation -- Microsatellite instability -- Endometrial cancer; Hematology, Experimental -- Periodicals; Oncology, Experimental -- Periodicals; Hematologic Diseases -- Periodicals; Neoplasms -- Periodicals; 616.1502705
• DOI: 10.1186/s40164-016-0061-2
• Languages: English
• ISSNs: 2162-3619

Abstract

Abstract Background Targeting BRAF V600E mutation has been proven effective in the treatment of several types of cancer. In endometrial adenocarcinoma, the BRAF V600E mutation has been rarely reported. Whether targeting BRAF oncogene may represent a plausible therapeutic strategy for the rare patients with BRAF-mutated endometrial cancer remains to be ascertained in prospective studies. Case presentation We report herein the case of a heavily pre-treated patient with recurrent microsatellite instability high (MSI-H) BRAF V600E mutated endometrial adenocarcinoma, which was successfully treated with the V600E targeting agent dabrafenib. After developing resistance to this agent, the MEK targeting agent trametinib was added to dabrafenib achieving again a therapeutic response. Conclusions This case shows that dabrafenib both as monotherapy and when combined with trametinib may exert significant therapeutic activity in heavily pretreated BRAF V600E mutated endometrial adenocarcinoma, and highlight potential benefits of personalized treatment in this disease.